Pharmaceuticals, Biotechnology and Life Sciences
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million
Advanced Oncotherapy, the developer of proton therapy systems for cancer treatment, has appointed Professor Stephen Myers OBE, Head of Medical Applications at CERN, as Executive Chairman of its subsidiary ADAM S.A.
Pfizer and Allergan have entered into a definitive merger agreement under which Pfizer will combine with Allergan in a transaction valued at about $160 billion.
Vertex Pharmaceuticals, a biotechnology company has appointed Pfizer’s Senior Vice president Michael J. Parini to the role of Executive Vice President and Chief Legal Officer.
A medical device company Akers Biosciences has appointed John J. Gormally as Chief Executive Officer from the global medical technology company Becton Dickinson
Biosense Webster has acquired Coherex Medical, Inc. a privately held medical device company based in Salt Lake City, Utah.
Sanofi and AstraZeneca have announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries.
Mylan’s subsidiaries were sued Warner Chilcott and Qualicaps in connection with the filing of an ANDA with the FDA for Mesalamine Delayed-release Capsules.